Name
Swixx Biopharma OÜ
Registry code
12741121
VAT number
EE101811486
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
23.10.2014 (9)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
82991 - Other business support service activities n.e.c.
-
-
-
-
-
-
Submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Laur Saar 29.08.1966 (58) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member | |
| Piret Tuul 24.04.1970 (54) | - | Board member | - | |
| A-Firmad OÜ 11442638 | - | - | - | Founder |
| 2019 11.06.2020 | 2020 01.06.2021 | 2021 09.06.2022 | 2022 02.06.2023 | 2023 28.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 633 981 € | 651 565 € | 821 591 € | 2 988 612 € | - |
| Net profit (loss) for the period | 23 410 € | 33 257 € | 40 650 € | 156 940 € | - |
| Profit Margin | 4% | 5% | 5% | 5% | - |
| Current Assets | 173 754 € | 222 242 € | 259 979 € | 641 665 € | - |
| Fixed Assets | 3 110 € | 5 371 € | 37 267 € | 36 962 € | - |
| Total Assets | 176 864 € | 227 613 € | 297 246 € | 678 627 € | - |
| Current Liabilities | 102 356 € | 119 848 € | 148 831 € | 373 271 € | - |
| Non Current Liabilities | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - |
| Share Capital | - | - | - | - | - |
| Equity | 74 508 € | 107 765 € | 148 415 € | 305 356 € | - |
| Employees | 3 | 4 | 6 | 20 | - |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 936 352.67 € | 275 613.05 € | 281 286.47 € | 24 |
| 2023 Q4 | 936 100.4 € | 194 330.6 € | 193 387.01 € | 23 |
| 2023 Q3 | 845 773.45 € | 183 757.37 € | 183 713.85 € | 23 |
| 2023 Q2 | 914 533.53 € | 252 816.84 € | 254 334.92 € | 22 |
| 2023 Q1 | 260 588.62 € | 174 387.57 € | 176 608.99 € | 23 |
| 2022 Q4 | 878 807.1 € | 184 870.2 € | 177 744.29 € | 23 |
| 2022 Q3 | 748 826.17 € | 157 737.54 € | 160 859.99 € | 23 |
| 2022 Q2 | 745 699.23 € | 147 550.81 € | 152 097.1 € | 21 |
| 2022 Q1 | 541 136.09 € | 137 766.1 € | 145 288.78 € | 22 |
| 2021 Q4 | 263 531.25 € | 60 648.08 € | 64 165.67 € | 8 |
| 2021 Q3 | 175 208.32 € | 37 773.38 € | 39 551.85 € | 7 |
| 2021 Q2 | 183 468.6 € | 39 501.96 € | 41 740.89 € | 6 |
| 2021 Q1 | 221 648.74 € | 68 547.82 € | 73 157.42 € | 6 |
| 2020 Q4 | 167 053.17 € | 35 265.72 € | 37 212.85 € | 6 |
| 2020 Q3 | 137 432.97 € | 33 141.3 € | 34 990.15 € | 5 |
| 2020 Q2 | 140 752.81 € | 30 675.12 € | 32 311.6 € | 4 |
| 2020 Q1 | 194 184.06 € | 52 312.78 € | 55 545.04 € | 4 |
